Drug Profile
CNM AgZn17
Alternative Names: CNM-AgZn17; CNM-ZnAgLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Clene Nanomedicine
- Class Anti-infectives; Antivirals; Elements
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
- Preclinical Burns; Wounds
- No development reported Viral infections
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in Viral-infections in USA (Topical)
- 27 Dec 2022 Safety and efficacy data from a phase II trial in COVID-19 released by the Clene Nanomedicine
- 20 Oct 2022 Clene Nanomedicine completes a phase II trial in COVID-2019 infections (In adults, In the elderly) in Brazil (PO) (NCT04610138)